The CLL Channel on VJHemOnc is supported by Johnson & Johnson. These supporters have no influence over the production of the content.
2:08
7-year follow-up of ibrutinib monotherapy for R/R and first-line CLL
Susan O’Brien
• 1 Dec 2018
03:12
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
• 15 Jan 2019